Hemab Therapeutics Holdings, Inc. (COAG)
NASDAQ: COAG · Real-Time Price · USD
31.00
-1.50 (-4.62%)
At close: Jul 2, 2026, 4:00 PM EDT
30.65
-0.35 (-1.13%)
After-hours: Jul 2, 2026, 6:25 PM EDT
Hemab Therapeutics Holdings Earnings Call Transcripts
Fiscal Year 2026
-
The company is advancing a pipeline of therapies for rare bleeding disorders, with its lead asset entering phase III and additional programs progressing in Factor VII deficiency and von Willebrand disease. Strong efficacy, regulatory alignment, and a robust financial position support global development plans.